Join
Live feed
·
PRReleasevia Quantisnow
LENZ Therapeutics Inc. logo

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

ByQuantisnow·Wall Street's wire, on your screen.
LENZ· LENZ Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LENZ (LENZ Therapeutics Inc.) and more on Quantisnow.